Doxacurium chloride Uses, Dosage, Side Effects and more
Doxacurium chloride chloride is a long-acting, nondepolarizing skeletal muscle relaxant for intravenous administration.
Doxacurium chloride chloride is a long-acting, nondepolarizing skeletal muscle relaxant. The neuromuscular block produced by doxacurium chloride may be antagonized by anticholinesterase agents. As with other nondepolarizing neuromuscular blocking agents, the more profound the neuromuscular block at reversal, the longer the time and the greater the dose of anticholinesterase required for recovery of neuromuscular function. Doxacurium chloride chloride is approximately 2.5 to 3 times more potent than pancuronium and 10 to 12 times more potent than metocurine.
| Attribute | Details |
|---|---|
| Trade Name | Doxacurium chloride |
| Availability | Discontinued |
| Generic | Doxacurium |
| Doxacurium Other Names | Doxacurium chloride |
| Type | |
| Formula | C56H78N2O16 |
| Weight | Average: 1035.2223 Monoisotopic: 1034.535134458 |
| Protein binding | Approximately 30%. |
| Groups | Approved |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
Uses
Doxacurium chloride chloride is a nondepolarizing neuromuscular blocking agent used as an adjunct to general anesthesia to facilitate tracheal intubation, and to provide skeletal muscle relaxation during surgical procedures.
Used to provide skeletal muscle relaxation as an adjunct to general anesthesia, for endotracheal intubation or to facilitate mechanical ventilation.
How Doxacurium chloride works
Doxacurium chloride chloride binds competitively to cholinergic receptors on the motor end-plate to antagonize the action of acetylcholine, resulting in a block of neuromuscular transmission (non-depolarizing). This action is antagonized by acetylcholinesterase inhibitors, such as neostigmine.
Toxicity
Overdosage with neuromuscular blocking agents may result in neuromuscular block beyond the time needed for surgery and anesthesia.
Drug Interaction
Unknown: zafirlukast, zafirlukast, ipratropium, ipratropium, albuterol / ipratropium, albuterol / ipratropium, formoterol / mometasone, formoterol / mometasone, albuterol / ipratropium, albuterol / ipratropium, fluticasone, fluticasone, pentamidine, pentamidine, budesonide, budesonide, dornase alfa, dornase alfa, zanamivir, zanamivir
Disease Interaction
Major: prematurity, burns, electrolyte imbalance, liver disease, myasthenia gravis, paresis, pulmonary impairModerate: obesity, renal dysfunction
Volume of Distribution
- 0.11-0.43 L/kg [Healthy Young Adult Patients]
- 0.17-0.55 L/kg [Kidney Transplant Patients]
- 0.17-0.35 L/kg [Liver Transplant Patients]
Half Life
99 minutes in normal healthy adults.
Clearance
- 2.66 mL/min/kg [Healthy Young Adult Patients]
- 1.23 mL/min/kg [Kidney Transplant Patients]
- 2.3 mL/min/kg [Liver Transplant Patients]
- 1.75 +/- 0.16 mL/min/kg [Elderly patients (70-83 yrs)]
- 2.54 +/- 0.24 mL/min/kg [younger patients (19-39 yrs)]
Elimination Route
In vivo data from humans suggest that NUROMAX is not metabolized and that the major elimination pathway is excretion of unchanged drug in urine and bile.
